SignalFDA/Bio
Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug
New CEO, $250M funding, and another cancer drug catalyst drive high relevance.
Context
What happened: Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment. The headline also notes a new CEO and a shot at another cancer drug.
Key numbers: $250 million planned raise.
Why it matters: The funding is tied to advancing the experimental cancer treatment into late-stage testing, alongside the leadership change.
Market: +3.8% today ($147.37), +39.4% YTD, 1.0x vol — as of 23:45 UTC
What changed
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment. The headline also notes a new CEO and a shot at another cancer drug.
Why it matters
The funding is tied to advancing the experimental cancer treatment into late-stage testing, alongside the leadership change.
Market: +3.8% today ($147.37), +39.4% YTD, 1.0x vol — as of 23:45 UTC
← Dashboard
Oct 14, 2026 04:50 PM ET